Every 10-Q that Indaptus Therapeutics, Inc. (INDP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow INDP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INDP filings page.
Indaptus Therapeutics, Inc. is a clinical-stage biotech that has halted further clinical development of its Decoy20 program and is actively evaluating strategic alternatives, including a potential investment in or acquisition of an operating business. During the quarter it also initiated a neurological and sleep research collaboration in China and engaged new scientific consulting focused on data-driven health and neurophysiological signals.
For the three months ended June 30, 2026, net loss narrowed to $1.8 million from $5.2 million a year earlier, driven by an 83% reduction in research and development expenses and a 37% decline in general and administrative costs as clinical activities and headcount were scaled back. For the six-month period, net loss fell to $4.3 million from $9.8 million.
Liquidity improved through a December 2025 preferred stock investment that converted into 111,000,000 common shares and a June 17, 2026 private placement of 20,000,000 common shares at $0.60 per share, generating approximately $12.0 million in gross proceeds. As of June 30, 2026, cash and cash equivalents were $7.6 million and certificates of deposit totaled $4.0 million. Management believes these resources fund operations through the second quarter of 2027, yet discloses substantial doubt about the company’s ability to continue as a going concern given ongoing losses, strategic uncertainty, and future financing needs.
Indaptus Therapeutics reported a Q1 2026 net loss of $2.54 million, improved from $4.53 million a year earlier, mainly because research and development spending fell to $0.49 million from $2.81 million as clinical activity was wound down. General and administrative expenses were stable at $1.67 million.
Cash and cash equivalents dropped to $1.50 million at March 31, 2026, after using $7.01 million in operating cash during the quarter. The company expects existing cash to fund operations only through the second quarter of 2026 and states there is substantial doubt about its ability to continue as a going concern.
All outstanding Series AA and Series AAA preferred shares issued in late 2025 converted into 111,000,000 common shares, bringing total shares outstanding to 113,242,324 at March 31, 2026. Indaptus has discontinued enrollment in its clinical studies and is evaluating strategic options for a post-investment transaction while keeping its immunotherapy platform as a potential asset.
Indaptus Therapeutics (INDP) filed its Q3 2025 10‑Q, reporting a net loss of $2,975,117 for the quarter and $12,736,466 for the nine months ended September 30, 2025. Operating expenses were $2,648,487 in Q3, with R&D at $1,517,723 and G&A at $1,130,764. Cash and cash equivalents were $5,825,639 at quarter‑end.
The company states there is substantial doubt about its ability to continue as a going concern. Management believes current cash funds operations into the first quarter of 2026 and is pursuing additional financing. During 2025, Indaptus raised capital via a $20.0 million SEPA (net proceeds approximately $1.74 million to date), $5.7 million of convertible notes (automatically converted on July 27, 2025 into 501,566 shares and pre‑funded warrants), and an ATM sale of 520,000 shares for net proceeds of about $2.25 million in September.
The company effected a 1‑for‑28 reverse stock split on June 26, 2025, regaining Nasdaq bid‑price compliance. Shares outstanding were 1,641,920 as of September 30, 2025; as context, 1,751,163 were outstanding as of November 11, 2025. Indaptus continues Phase 1 development of Decoy20, including a combination study with tislelizumab, and has paused further enrollment pending additional efficacy evaluations.
Indaptus Therapeutics is a clinical-stage biotechnology company developing Decoy20, a systemically administered immunotherapy. For the six months ended June 30, 2025, the company reported a net loss of $9.76 million and used approximately $9.1 million of cash in operations. Cash and cash equivalents were $6.16 million at period end, which management estimates funds operations into the fourth quarter of 2025 under the current plan. The company had an accumulated deficit of $70.2 million and recorded a stockholders equity (deficit) of $(1.67) million as of June 30, 2025, with management stating there is substantial doubt about the companys ability to continue as a going concern.
The increase in research and development expense to $4.98 million for the six months (up 50.6% year-over-year) was driven mainly by higher clinical trial costs for the Phase 1 Decoy20 program. Management completed several financings during the period: a January 2025 private placement raising approximately $2.0 million net, sales under a Standby Equity Purchase Agreement (SEPA) that generated approximately $1.75 million net, and a June 2025 private placement of convertible notes with gross proceeds of approximately $5.7 million (measured at fair value of $6.50 million on June 30). The company effected a 1-for-28 reverse stock split to regain Nasdaq minimum bid price compliance, and subsequent conversion of the Notes in July 2025 and related warrant issuances resulted in the company satisfying the Nasdaq minimum stockholders equity requirement of $2.5 million.